OD-doxy-PNV-COVID-19 Old Drug " DOXY " for Prevention of New Virus " COVID-19 "

Hedi Gharsallah

Status and phase: Completed; Phase 3

Conditions: Covid19

Treatments: Drug: Doxycyclin

Study type: Interventional

Funder types: Other; NETWORK

Identifiers

NCT04584567

UR17DN05

Details and patient eligibility

About

Given the urgency of having guidelines for the management of COVID-19 in the current epidemic context and the lack of specific pharmacological treatment, Military Health recommends the launch of a multicenter, randomized, double-blind, interventional clinical trial.

The aim of this study is to evaluate the efficacy of a combination of two treatments, low-dose doxcycline (100 mg/day) and Zinc (15 mg/day) (dietary supplement) in the primary prevention of COVID-19 infection in health care professionals in Tunisia compared to two control groups.

Enrollment: 194 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• No self-medication with study drugs or antivirals
• Negative COVID19 diagnosis confirmed by PCR and negative Elisa antibody assay
• No signs of COVID19
• Having given consent for the study

Exclusion criteria

Participation in other clinical trials aimed at primary prevention of VIDOC infection19

• Liver failure
• Known allergy to the study product
• Pregnancy or breastfeeding
• Vitamin A and E treatment in progress

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

194 participants in 3 patient groups, including a placebo group

DOXY ZINC

Experimental group

Description:

Doxycycline daily dosing (100mg) Zinc daily dosing (15mg)

Treatment:

Drug: Doxycyclin

DOXY PLACEBO

Placebo Comparator group

Description:

Doxycycline daily dosing (100mg) placebo of Zinc

Treatment:

Drug: Doxycyclin

PLACEBO

Placebo Comparator group

Description:

placebo of Doxycycline daily dosing placebo of Zinc

Treatment:

Drug: Doxycyclin